Metis Therapeutics
Series B
METiS Therapeutics: Developing small molecule drugs for diverse illnesses through integrated discovery.
Founded
2017METiS Therapeutics: Developing small molecule drugs for diverse illnesses through integrated discovery.
Founded with a mission to revolutionize drug discovery, METiS Therapeutics leverages cutting-edge technologies to develop novel therapeutics for serious diseases. The company focuses on integrating Artificial Intelligence (AI), Machine Learning (ML), and Molecular Dynamics (MD) to create innovative small molecule drugs, biologics, and advanced nucleic acids. METiS' lead programs utilize AI and high-throughput in vivo screening to discover unique lipid nanoparticles (LNPs) with exceptional targeting capabilities.
Notable figures affiliated with METiS Therapeutics include experts in AI-driven drug discovery and seasoned professionals from the pharmaceutical industry. The company has attracted significant investment from leading venture capital firms, underscoring its potential impact. Key achievements include the development of proprietary LNPs that enhance drug delivery and efficacy. METiS Therapeutics is poised to make a substantial impact on the treatment of serious diseases through its pioneering approach to integrated drug discovery.
Companies similar to Metis Therapeutics include Metaphore Biotechnologies, Empress Therapeutics, Biolexis Therapeutics and Iambic Therapeutics.
Metis Therapeutics was founded in 2017.
Metis Therapeutics' headquarters is located in Cambridge, MA, US.
Metis Therapeutics' most recent funding round was for $75M (USD) in April 2022.
As of Apr 5, 2022, Metis Therapeutics has raised a total of $261M (USD).
Metis Therapeutics has 36 employees as of Feb 4, 2024.
Biolexis Therapeutics
biolexistx.com
